Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced today that it has completed the submission of a New Application (NDA) to the U.S. Food and Administration (FDA) seeking approval for telaprevir, Vertex’s investigational treatment for people with C.


Read more

Related posts

Leave a Reply